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to BIM-23A758, the SSTR2/D2R chimeric compound BIM-
23A760 as well as the individual SSTR2 and D2R agonistic 
compounds BIM-23023 and BIM-53097 induced no or only 
minor antitumor responses in the examined NET cell lines. 
Taken together, our findings suggest that the novel SSTR2/
D2R chimeric compound BIM-23A758 might be a promising 
substance for the treatment of NETs highly expressing SSTR2 
and D2R. In particular, a sufficient expression of the short 
transcript variant of DR2 might play a pivotal role for effec-
tive treatment.  © 2013 S. Karger AG, Basel 
 Introduction 
 Treatment options for neuroendocrine tumors (NETs) 
of the gastroenteropancreatic (GEP) system are limited. 
As more than 85% of NETs are metastatic at the time of 
diagnosis, only few patients have a chance for curative 
surgery. Thus, currently available therapy (bio- and che-
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 Abstract 
 The majority of neuroendocrine tumors (NETs) of the gastro-
enteropancreatic system coexpress somatostatin receptors 
(SSTRs) and dopamine type 2 receptors (D2R), thus provid-
ing a rationale for the use of novel SSTR2/D2R chimeric com-
pounds in NET disease. Here we investigate the antitumor 
potential of the SSTR2/D2R chimeric compounds BIM-
23A760 and BIM-23A758 in comparison to the selective 
SSTR2 agonist BIM-23023 and the selective D2R agonist
BIM-53097 on human NET cell lines of heterogeneous origin. 
While having only minor effects on human pancreatic and 
bronchus carcinoid cells (BON1 and NCI-H727), BIM-23A758 
induced significant antitumor effects in human midgut car-
cinoid cells (GOT1). These effects involved apoptosis induc-
tion as well as inhibition of mitogen-activated protein kinase 
and Akt signaling. Consistent with their antitumor response 
to BIM-23A758, GOT1 cells showed relatively high expres-
sion levels of SSTR2 and D2R mRNA. In particular, GOT1 cells 
highly express the short transcript variant of D2R. In contrast 
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motherapy, surgical, debulking, molecular-targeted ther-
apy, and peptide receptor-based radiotherapy) focuses on 
symptom control and disease stabilization. 
 Somatostatin (SST) is a cyclopeptide, consisting of 14 
or 28 amino acids (SST-14 and SST-28), which serves as 
an important physiological inhibitor of endocrine and 
exocrine secretion  [1, 2] . SST has been shown to affect the 
release of growth hormone as well as several gastrointes-
tinal tract hormones. SST-14 and SST-28 mediate their 
effects through interaction with five receptors (SSTR1–5) 
belonging to the family of G protein-coupled receptors 
(GPCRs)  [3] . All five receptor subtypes have been shown 
to inhibit cell proliferation in vitro, whereas SSTR2 and 
SSTR3 may additionally induce apoptosis  [4] . These di-
rect antitumor effects appear to be regulated primarily 
through activation of phosphotyrosine phosphatases and 
mitogen-activated protein kinase (MAPK) signaling  [5] . 
In addition to its inhibitory effect on growth factor and 
hormone secretion, SST has been shown to exert a num-
ber of other indirect antitumor actions including antian-
giogenic and immunomodulatory effects  [6] . 
 The clinical utility of natural SST is limited by its very 
short circulation half-life (1.5–3 min). A number of syn-
thetic SST analogues with improved pharmacokinetic 
profiles have been developed of which octreotide and lan-
reotide are now widely used for the biotherapy of acro-
megaly and GEP-NETs  [7, 8] . Both compounds provide 
excellent control of hypersecretory-associated symp-
toms. In contrast to their natural counterparts which bind 
to all five SSTR subtypes with high affinity, octreotide and 
lanreotide predominantly bind to SSTR2  [9] . 
 The results of several uncontrolled clinical studies in 
NETs also suggest octreotide and lanreotide possess anti-
proliferative activity, mostly resulting in tumor stabiliza-
tion  [8] . The PROMID study, a prospective placebo-con-
trolled clinical phase IIIb study with octreotide long-act-
ing release 30 mg in 85 patients with well-differentiated 
metastatic midgut NETs, reported a significant effect on 
median time to tumor progression with 14.3 months in 
the octreotide long-acting release group versus 6 months 
in the placebo group  [10] .
 It is now known that SSTR subtypes can undergo 
homo- or heterodimerization, thereby enhancing ligand 
binding, internalization and signal transduction  [11] . 
SSTRs have also been demonstrated to form heterodi-
mers with other G protein-coupled receptors such as the 
μ-opioid or the dopamine type 2 receptor (D2R)  [12] . 
Thus, novel SST analogues which bind with high affinities 
to multiple SSTR subtypes and chimeric compounds 
binding SSTRs and D2R have been developed. Such com-
pounds have been shown to be more effective in suppress-
ing growth hormone and prolactin secretion from cul-
tured human growth hormone-secreting pituitary tu-
mors than monoreceptor ligands alone  [13–15] . As the 
majority of GEP-NETs coexpress SSTRs and D2R, such 
compounds might offer novel therapeutic opportunities 
 [16, 17] . 
 In this study we analyze the effects of the novel SSTR2/
D2R chimeric compounds BIM-23A760 and BIM-
23A758 in comparison to the selective SSTR2 agonist 
BIM-23023 and the selective D2R agonist BIM-53097 ( ta-
ble 1 ) on three human NET cell lines of heterogeneous 
origin. Although a current clinical phase 2 study with 
BIM-23A760 in NETs (NCT01018953) has been termi-
nated, our data with BIM-23A758 can demonstrate as a 
proof of principle the antitumoral effects of SSTR2/D2R 
chimeric compounds in NETs preselected for coexpres-
sion of SSTRs and D2R. 
 Materials and Methods 
 Cell Culture 
 Human pancreatic neuroendocrine BON1 tumor cells were 
kindly provided by R. Göke (Marburg, Germany) and were cul-
tured in DMEM/F12 (1: 1) medium (Gibco/Invitrogen, Karlsruhe, 
Germany). Human midgut carcinoid GOT1 cells were kindly pro-
vided by Ola Nilsson (Göteborg, Sweden). Human bronchopul-
monary neuroendocrine NCI-H727 tumor cells were purchased 
from ATCC (Manassas, Va., USA). GOT1 and NCI-H727 cells 
were cultured in RPMI-1640 medium (PAA, Pasching, Austria). 
All media were supplemented with 10% FCS (Biochrom, Berlin, 
Germany), 1% penicillin/streptomycin (Gibco) and 0.4% ampho-
tericin B (Biochrom). GOT1 culture medium was additionally 
supplemented with 0.135 IU/ml insulin and 5 μg/ml apo-transfer-
rin. All cells were cultured at 37  °  C in a 5% CO 2 atmosphere.
 Reagents 
 BIM-23A760, BIM-23A758, BIM-23023 and BIM-53097 were 
kindly provided by Michael Culler (Ipsen, Milford, Mass., USA). 
Compounds BIM-23A760, BIM-23A758 and BIM-23023 were dis-
Table 1.  Human SSTR subtype specificity [Ki; dissociation con-
stant (nM)]. Zhang S, Datta R and Culler MD 2013 [pers. com-
mun.]
Compound SSTR1 SSTR2 SSTR3 SSTR4 SSTR5 D2R
BIM-23A758 549 0.2 >1,000 >1,000 43 14
BIM-23A760 142 0.2 40 471 6 5
BIM-23023 >1,000 0.2 87 >1,000 5 >1,000
BIM-53097 ND ND ND ND ND 51
 ND = Not done.
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solved in 0.2% BSA. BIM-53097 was initially dissolved in 0.15% 
ethanol; further dilutions were performed in 0.2% BSA. Therefore, 
control groups always contained 0.15% ethanol. Sulpiride was pur-
chased from Sigma-Aldrich (St. Louis, Mo., USA).
 Assessment of Cell Viability 
 All compounds were added once at the beginning of the ex-
periment for the indicated time points.  Metabolic activity was 
measured with Cell Titer 96 AQ ueous One Solution Cell Prolifera-
tion Assay (Promega, Madison, Wis., USA) according to the man-
ufacturer’s instructions. Following 3 h of incubation with Cell Ti-
ter 96 solution, absorbance at 492 nm was determined using an 
ELISA plate reader.
 RNA Isolation and Quantitative RT-PCR 
 RNA isolation and quantitative RT-PCR (qRT-PCR) were per-
formed as described previously  [18] using the following primers 
for amplification: human SSTR2 forward and reverse: 5 ′ -GGCAT-
GTTTGACTTTGTGGTG-3 ′ and 5 ′ -GTCTCATTCAGCCGGG-
ATTT-3 ′ , human SSTR5 forward and reverse: 5 ′ -CTGGTGTTT-
GCGGGATGTT-3 ′ and 5 ′ -GAAGCTCTGGCGGAAGTTGT-3 ′ , 
human D2R-long (L) forward and reverse: 5 ′ -CAACTGTACT-
CACCCCGAG-3 ′ and 5 ′ -GGCTGTACCGGGTCCTCTC-3 ′ , hu-
man D2R-short (S) forward and reverse: 5 ′ -CACTAAAGGAG-
GCTGC-3 ′ and 5 ′ -GGCTGTACCGGGTCCTCTC-3 ′ , and human 
GAPDH forward and reverse: 5 ′ -ACCCACTCCTCCACCTTT-
GA-3 ′ and 5 ′ -CTGTTGCTGTAGCCAAATTCGT-3 ′ . PCR was 
performed using Platinum Taq DNA Polymerase (Invitrogen, 
Carlsbad, Calif., USA) and SYBR Green under the following con-
ditions: 35 cycles of denaturing at 94  °  C for 30 s, annealing at 55  °  C 
(D2R: 62   °   C) for 30 s and extension at 72   °   C for 30 s. Relative ex-
pression levels were calculated with the ΔΔC t method  [19] using 
internal GAPDH for normalization. 
 Protein Extraction, Immunoprecipitation and Western 
Blotting 
 Protein extraction and Western blotting were done as previ-
ously described in detail  [20] . Primary antibodies used were pAkt 
(Ser473), pan-Akt, pMEK, MEK, pERK-1/2, ERK-1/2, pp70S6K, 
p70S6K, p4E-BP1, 4E-BP1, pMDM2, cyclin D1, cyclin D3, p27kip1, 
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 Fig. 1. BIM-23A758 potently decreases GOT1 cell viability.  BON1, NCI-H727 and GOT1 cells were incubated 
with indicated concentrations of BIM-23A760 ( a ) or BIM-23A758 ( b ) for 72 and 144 h, respectively. Cell viabil-
ity was measured with the Cell Titer 96 kit (Promega). Shown are the mean values ± SD of three independently 
performed experiments (n = 6/group for each experiment).  *  p < 0.05 vs. untreated control. 
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
10
/2
0/
20
14
 1
:3
0:
59
 P
M
 SSTR2/D2R Chimeric Compound
BIM-23A758 
Neuroendocrinology 2013;98:128–136
DOI: 10.1159/000353784
131
PARP, caspase-3, Bcl-XL (Cell Signaling, Danvers, Mass., USA), 
Bcl-2  (BD, Franklin Lakes, N.J., USA), cleaved caspase-3 (R&D 
Systems, Wiesbaden-Nordenstadt, Germany) and β-actin (Ab-
cam, Cambridge, UK). 
 Quantification of DNA Fragmentation and Cell Cycle 
Analysis 
 The rate of apoptotic cell death was quantified by determining 
DNA fragmentation according to Nicoletti et al.  [21] . Briefly, cells 
were incubated for 24 h in a hypotonic buffer (0.1% sodium citrate, 
0.1% Triton X-100, 50 μg/ml propidium iodide) and analyzed by 
flow cytometry on a FACSCalibur analyzer (BD) using CellQuest 
software (BD). Nuclei to the left of the G 1 -peak containing hypo-
diploid DNA were considered apoptotic.
 Statistical Analysis 
 Statistical analysis was done using a two-tailed Student t test.
p < 0.05 was considered statistically significant.
 Results 
 BIM-23A758 Decreases GOT1 Cell Viability 
 To test the antitumor potential of  SSTR2/D2R chime-
ric compounds in different human NET cell lines, pan-
creatic BON1 cells, bronchus typical carcinoid NCI-H727 
cells and midgut GOT1 cells were incubated with increas-
ing concentrations of BIM-23A760, BIM-23A758, BIM-
23023 or BIM-53097 for 72 h and 144 h, respectively. In 
the low-dose range (tested concentrations: 1, 10 and 100 
n M ), none of the tested cell lines responded to any of the 
substances with significant antitumor effects (data not 
shown). At higher concentrations (tested concentrations: 
500, 1,000, 2,000 and 4,000 n M ), BIM-23A760 induced 
minor but significant short-term effects in reducing cell 
viability – especially in BON1 cells (max. reduction of cell 
viability at 500 n M to approx. 93%, p < 0.05;  fig. 1 a). In 
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 Fig. 2. Effect of monoreceptor ligands on NET cell viability. BON1, NCI-H727 and GOT1 cells were incubated 
with indicated concentrations of BIM-23023 ( a ) or BIM-53097 ( b ) for 72 and 144 h, respectively. Cell viability 
was measured with the Cell Titer 96 kit (Promega). Shown are the mean values ± SD of three independently per-
formed experiments (n = 6/group for each experiment).  *  p < 0.05 vs. untreated control. 
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contrast, BIM-23A758 dose- and time-dependently de-
creased the viability of GOT1 cells to approximately 56% 
while having no or only minor effects on the viability of 
BON1 and NCI-H727 cells ( fig. 1 b). GOT1 cells were also 
slightly responsive to the D2R agonist BIM-53097 (max. 
reduction of cell viability at 500 n M to 91%, p < 0.05; 
 fig. 2 b). However, none of the tested cell lines was respon-
sive to the SSTR2 agonist BIM-23023 ( fig. 2 a).
 GOT1 Cells Have High Expression Levels of SSTR2 
and D2R 
 To identify the molecular determinants of response to 
the SSTR2/D2R chimeric compounds, basal mRNA levels 
of SSTR2, SSTR5 and the two splice variants of D2R, 
D2R-L and D2R-S, were analyzed by qRT-PCR in NCI-
H727, BON1 and GOT1 cells. All three cell lines expressed 
the tested receptor subtypes ( fig. 3 ). Consistent with their 
strong response to BIM-23A758 in cell viability assays, 
GOT1 cells showed the highest expression levels of 
SSTR2, D2R-L and D2R-S mRNA among the tested cell 
lines ( fig. 3 ). In contrast, GOT1 cells expressed low levels 
of SSTR5 mRNA ( fig. 3 d).
 Expression Profiles of SSTR1 and SSTR3 
 The fact that relatively high doses of BIM-23A758 were 
needed to achieve significant antitumor effects in GOT1 
cells ( ≥ 1,000 n M ) might possibly reflect a contribution of 
other SSTRs with lower binding affinities. We thus addi-
tionally analyzed basal mRNA levels of SSTR1, SSTR3 and 
SSTR4 by qRT-PCR. While SSTR4 was not detectable in 
any of the tested cell lines, GOT1 cells showed moderate 
expression of SSTR1 and SSTR3 ( fig. 4 ), but the highest 
relative expression was observed in BON1 cells.
 Sulpiride Partially Inhibits BIM-23A758-Induced 
Antitumor Effects in GOT1 Cells 
 To assess the role of D2R in the cytotoxic response to 
BIM-23A758, GOT1 cells were cotreated with BIM-
23A758 and the selective D2R antagonist sulpiride. As 
shown in  figure 5 , sulpiride could partially rescue GOT1 
cells from BIM-23A758-induced antitumor effects.
 BIM-23A758 Induces Apoptosis in GOT1 Cells 
 In order to identify the mechanism responsible for the 
decrease of cell viability in response to BIM-23A758, we 
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 Fig. 3. GOT1 cells have high expression 
levels of SSTR2 and D2R. mRNA expres-
sion levels of D2R-L ( a ), D2R-S ( b ), SSTR2 
( c ) and SSTR5 ( d ) in BON1, NCI-H727 
and GOT1 cells were verified by qPCR.
Receptor mRNA expression in BON1 and 
NCI-H727 cells relative to NCI-H727 cells 
was calculated using the comparative ΔΔC t 
method and internal GAPDH for normal-
ization. Shown are the mean values ± SD
of three independently performed experi-
ments (n = 2/group for each experiment). 
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performed FACS analysis of GOT1 cells treated with 
BIM-23A760, BIM-23A758, BIM-23023 or BIM-53097. 
As shown in  figure 6 a, BIM-23A758 increased the frac-
tion of cells with subG1-DNA content. Specific induction 
of apoptosis was confirmed by decreased Bcl-XL and
Bcl-2 protein expression and induction of cleaved cas-
pase-3 ( fig. 6 b). BIM-23A758 treatment resulted in a rel-
ative decrease of cells in G0/1, S and G2M, likely due to 
increased subG1, while Western blot analysis showed no 
significant changes in the expression of cyclin D1, cyclin 
D3 and p27kip1 (data not shown).
 BIM-23A758 Inhibits Akt and Erk Signaling in GOT1 
Cells 
 It has previously been reported that SSTR2/D2R chi-
meric molecules can affect Akt and MAPK signaling in a 
cell type-specific manner  [22] . Consistent with its antitu-
mor effect, BIM-23A758 significantly inhibited Akt and 
MAPK signaling in GOT1 cells ( fig. 7 ). In addition, BIM-
23A758 inhibited the phosphorylation of the Akt down-
stream targets p70S6K, 4E-BP1 and pMDM2 ( fig. 7 ).
 Discussion 
 In this study we tested the antitumor potential of the 
novel SSTR2/D2R chimeric compounds BIM-23A760 
and BIM-23A758 in comparison to the selective SSTR2 
agonist BIM-23023 and the selective D2R agonist BIM-
53097 on three human NET cell lines of heterogeneous 
origin. We show that BIM-23A758 is effective in the hu-
man midgut carcinoid cell line GOT1, while having only 
minor effects on human pancreatic BON1 and human 
bronchus carcinoid NCI-H727 cells, although NCI-H727 
cells express relatively high levels of SSTRs compared to 
other NET cell lines  [23] . 
 Different responses to SSTR2/D2R chimeras seem 
likely to be dependent on cell type-specific SST and do-
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 Fig. 4. mRNA expression levels of SSTR1 
and SSTR3 in NET cells. mRNA expression 
levels of SSTR1 ( a ) and SSTR3 ( b ) in BON1, 
NCI-H727 and GOT1 cells were deter-
mined by qPCR.  Receptor mRNA expres-
sion in BON1 and NCI-H727 cells relative 
to NCI-H727 cells was calculated using the 
comparative ΔΔC t method and internal 
GAPDH for normalization. Shown are the 
mean values ± SD of three independently 
performed experiments (n = 2/group for 
each experiment). 
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 Fig. 5. Sulpiride partially inhibits BIM23A758-induced antitumor 
effects in GOT1 cells. GOT1 cells were incubated with BIM-
23A758 (4,000 n M ), sulpiride (100 μ M ), or a combination of both 
for 72 h. Cell viability was measured with the Cell Titer 96 kit (Pro-
mega). Shown are the mean values ± SD of three independently 
performed experiments (n = 6/group for each experiment).  *  p < 
0.05 vs. untreated control;  + p < 0.05 vs. BIM-23A758-treated cells. 
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pamine receptor expression profiles and individual re-
ceptor signaling. Indeed, qRT-PCR revealed that GOT1 
cells – compared to NCI-H727 and BON1 cells – express 
high levels of both SSTR2 and D2R. In particular, GOT1 
cells highly express the short transcript variant of D2R. 
Though both isoforms of D2R can transduce the intra-
cellular signal correctly  [24] , the expression of D2R-S 
seems more important for a favorable growth inhibitory 
response to dopamine agonists in pituitary adenomas 
than the expression of D2R-L  [25–27] . It has also been 
shown that D2R-L is mostly retained in the perinuclear 
region around the Golgi apparatus, whereas D2R-S is 
predominantly localized at the plasma membrane and 
might therefore be more accessible to dopamine agonists 
 [28] . 
 It should be noted that the expression of D2R in GEP-
NETs, compared to pituitary adenomas or normal brain 
tissue, is extremely low  [22, 29] . However, constitutive or 
ligand-induced formation of SSTR/D2R homo- or het-
erodimers may lead to increased functional activity  [12] . 
Thus, even low receptor densities might be sufficient to 
yield potent antitumor effects in response to novel SSTR/
D2R chimeric compounds. GOT1 cells were hardly re-
sponsive to the single SSTR2 and D2R ligands BIM-23023 
and BIM-53097, while they were responsive to the SSTR2/
D2R chimeric compound BIM-23A758. Both dopamine 
and SST activity were required for the observed antitu-
mor effect of BIM-23A758 as treatment with the dopa-
mine antagonist sulpiride could only partially block the 
chimera effect. These findings are consistent with a study 
by Saveanu et al.  [30] who demonstrated that combined 
treatment with sulpiride and an SSTR2 antagonist was 
required to achieve full reversal of the growth hormone-
suppressing effect of the SSTR2/D2R chimeric compound 
BIM-23A287 on human pituitary somatotroph adenoma 
cells  [30] .
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 Fig. 6. BIM-23A758 induces apoptosis in 
GOT1 cells.  GOT1 cells were incubated 
with BIM-23A760, BIM-23A758, BIM-
23023 or BIM-53097 (4,000 n M each) for
72 h ( a ) or 48 h ( b ).  a  Subsequently, the 
fraction of cells with subG1 content was ex-
amined by flow cytometry. Shown is the 
mean value ± SD of four independently 
performed experiments ( *  p < 0.05).  b  Pro-
tein expression of Bcl-XL, Bcl-2, cleaved 
caspase-3 and β-actin loading control were 
evaluated by Western blot. Shown is one 
representative blot out of three performed. 
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 Fig. 7. BIM-23A758 inhibits Akt- and Erk signaling in GOT1 cells. 
 GOT1 cells were incubated with BIM-23A758 (4,000 n M ) for 2 h. 
Subsequently, protein expression of phosphorylated and total 
MEK, Erk1/2, Akt, p70S6K, 4E-BP1 and phosphorylated MDM2 
was evaluated by Western blot analysis. Shown is one representa-
tive blot out of three performed. 
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 However, it cannot be excluded that the lack of respon-
siveness to BIM-23023 was due to the compound as 
GOT1 cells xenografted to nude mice is a well-established 
model for peptide receptor-based radiotherapy with SST 
analogues  [31] . As we did not test any other SSTR2 ago-
nists, the missing antitumoral effect of BIM-23023 is no 
evidence to conclude that GOT1 cells in general fail to 
respond to SSTR2 agonists.
 In contrast to previous studies on pituitary cells  [32] , 
we employed relatively large doses of BIM chimeras 
(500–4,000 n M ) as low doses up to 100 n M had no sig-
nificant antitumor effect on the tested NET cell lines. This 
observation might possibly reflect the contribution of 
other SSTRs (e.g. SSTR3) with lower binding affinities 
( table 1 ). The fact that GOT1 responded to BIM-23A758 
but not to BIM-23A760 might be attributed to slightly 
different binding affinities for the SSTR1–5 subtypes and 
D2R ( table 1 ). Successful treatment with chimeric com-
pounds might thus require a perfect match between re-
ceptor profile and binding affinities.
 In order to reveal the signaling pathways implicated in 
BIM-23A758-induced antiproliferative and apoptotic ef-
fects we analyzed the activation status of MAPK and Akt 
signaling. While dopamine-induced antiproliferative and 
apoptotic effects have been shown to be primarily medi-
ated by p38 MAPK and Erk  [24, 33, 34] , SSTR-induced 
antitumor action involves the inhibition of PI(3)K/Akt 
signaling  [35] . In our study, BIM-23A758 potently inhib-
ited Akt and its downstream targets p70S6K, 4E-BP1 and 
MDM2 in GOT1 cells. However, while previous studies 
have demonstrated an increase of ERK1/2 phosphoryla-
tion in response to dopamine or SSTR2/D2R chimeric 
compounds in various cell types  [22, 33, 34] , BIM-23A758 
potently decreased ERK1/2 phosphorylation in GOT1 
cells. Consistent with our results, a recent study reported 
inhibition of ERK1/2 signaling in NCI-H727 cells after 
treatment with the SSTR3/DR2 chimeric compound 
BIM-23A761  [22] . These data suggest that Erk1/2 phos-
phorylation or dephosphorylation in response to D2R ac-
tivation is cell type-specific.
 In conclusion, our data show that NET cells of hetero-
geneous origin respond differently to specific SSTR2 ago-
nistic, D2R agonistic and SSTR2/D2R chimeric com-
pounds. The extent of response seems to depend on the 
individual SST and dopamine receptor profile. In partic-
ular, a sufficient expression of the short transcript variant 
of DR2 might play a pivotal role for effective treatment. 
 To our knowledge, data on BIM-23A758 pharmakoki-
netics are not available. In contrast to in vitro data, clini-
cal studies have revealed that chronic administration of 
BIM-23A760 in humans leads to the production of a me-
tabolite which gradually accumulates and interferes with 
the activity of the parent compound  [36] . Therefore, both 
BIM-23A760 and BIM-23A758 are currently not under 
consideration for clinical use, but should rather be con-
sidered as prototypes for this chimeric class of com-
pounds. Consequently, efforts are ongoing to create opti-
mized second generation chimera, which might be a 
promising treatment strategy for NETs expressing an ap-
propriate receptor profile.
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